Evidence map›Paper›PMID 33408885›Full record

ReviewJournal of breast cancer2020

Application of Biomarkers for the Prediction and Diagnosis of Bone Metastasis in Breast Cancer.

Feiqi Liu, Jianji Ke, Yanqiu Song

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of breast cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone.International journal of molecular sciences · 2021
    Review
  5. A review of advances in the last decade on targeted cancer therapy usingAmerican journal of nuclear medicine and molecular imaging · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Feiqi LiuDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, China.ORCID 0000-0003-2287-1758
Jianji KeDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.ORCID 0000-0001-5199-0436
Yanqiu SongDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, China.ORCID 0000-0002-1326-1416

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most common metastatic site of breast cancer is the bone. Metastatic bone disease can alter the integrity of the bone and cause serious complications, thereby greatly reducing health-related quality of life and leading to high medical costs. Although diagnostic methods and treatments for bone metastases (BM) are improving, some patients with early breast cancer who are at high risk of BM are not diagnosed early enough, leading to delayed intervention. Moreover, whole-body scintigraphy cannot easily distinguish BM from non-malignant bone diseases. To circumvent these issues, specific gene and protein biomarkers are being investigated for their potential to predict, diagnose, and evaluate breast cancer prognosis. In this review, we summarized the current biomarkers associated with BM in breast cancer and their role in clinical applications to assist in the diagnosis and treatment of BM in the future.

Indexed as

BiomarkersBone neoplasmsBreast neoplasmsPrognosis

Identifiers

PMID33408885
PMCPMC7779727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.